All In Biotech

Drug Trial Radar · NCT02503644

Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis

A Randomized, Double-blind, Placebo-controlled, Multicentre Proof-of-concept Trial of IVA337 in the Treatment of Diffuse Cutaneous Systemic Sclerosis

Last checked: Nov 19, 2026Latest source record: Mar 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 145 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

145

Actual

Start

Oct 29, 2015

Primary completion

Oct 2018

Study completion Oct 12, 2018

Sponsor

Lead sponsor
Inventiva PharmaIndustry
Sponsor type
Industry
First posted
Jul 21, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Systemic sclerosis (SSc), or scleroderma is a connective tissue disease of autoimmune origin. It is a life-threatening orphan disease with severe physical and psychosocial consequences. IVA337 has a novel mechanism of action and this study is designed to compare IVA337 at two dose levels with a placebo control treatment. Patients will be unaware of the treatment they are receiving and will be randomized to one of three treatment arms , either IVA337 400mg bid, IVA337 600mg bid or placebo bid. They will receive drug for 48 weeks and during that time assessments will be made to monitor both the efficacy and safety of the treatment.

Conditions

  • Scleroderma, Diffuse
  • Diffuse Cutaneous Systemic Sclerosis

Interventions

  • IVA337Drug

    Capsules of 200mg IVA337

  • PlaceboDrug

    Identical capsules without active substance

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Measurement of skin thickness by the Modified Rodnan Skin Score (MRSS)Time frame: 48 weeks

Locations

49 sites in 10 countries. Site status is shown where the registry gives one.

  • University Multiprofile Hospital for Active Treatment - Dr. Georgi Stranski

    Pleven, Bulgaria

  • Multiprofile Hospital for Active Treatment Plovdiv

    Plovdiv, Bulgaria

  • University Multiprofile Hospital for Active Treatment -Kaspela

    Plovdiv, Bulgaria

  • University Multiprofile Hospital for Active Treatment - "Sveti Ivan Rilski"

    Sofia, Bulgaria

  • Hôpital Pellegrin

    Bordeaux, France

  • CHRU de Lille- Hôpital Claude Huriez

    Lille, France

  • Hopital Cochin

    Paris, France

  • University Hospital of Strasbourg

    Strasbourg, France

  • Kerckhoff-Klinik

    Bad Nauheim, Germany

  • Charité- Universitätsmedizin Berlin

    Berlin, Germany

  • Chaité-Universtätsmedezin Berlin

    Berlin, Germany

  • Klinik fur Dermatologie und Venerologie der Universitat zu Köln

    Cologne, Germany

  • Univertaetsklinikum Carl Gustav Carus

    Dresden, Germany

  • University of Erlangen-Nuremberg

    Erlangen, Germany

  • CIRI GmbH Centrum für Innovative Diagnostik und Therapie

    Frankfurt, Germany

  • University Medical Center Freiburg

    Freiburg im Breisgau, Germany

  • Kilinik für Hautkrankenheiten

    Münster, Germany

  • Universtätsklinik Ulm

    Ulm, Germany

  • Istituto di Clinica Medica Generale Polo Didattico

    Ancona, Italy

  • Azienda Ospedalaria Spedali Civili di Brescia

    Brescia, Italy

  • Azienda Ospedaliera Universitaria Careggi

    Florence, Italy

  • Ospedale San Salvatore ASL L'Aquila

    L’Aquila, Italy

  • Azienda Ospedaliera Universitaria Federico II

    Naples, Italy

  • University of Padova

    Padova, Italy

  • Ospedale di Alta Specializzazione "San Camillo"

    Roma, Italy

  • Policlinico Umberto I

    Roma, Italy

  • Universita degli Studi de Verona

    Verona, Italy

  • Leiden University Medical Center

    Leiden, Netherlands

  • Erasmus MC Universitair Medisch Centrum Rotterdam

    Rotterdam, Netherlands

  • Centrum Miriada Prywatny

    Bialystok, Poland

  • University Hospital in Bydgoszcz

    Bydgoszcz, Poland

  • CM Plejady

    Krakow, Poland

  • Reumed

    Lublin, Poland

  • Medycine Centrum Hetmanska Poznan

    Poznan, Poland

  • Centrum Medyczne Oporow

    Wroclaw, Poland

  • University Medical centre Ljubljana

    Ljubljana, Slovenia

  • University Medical Centre Maribor

    Maribor, Slovenia

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain

  • Hopital Universitario Gregorio Marañon

    Madrid, Spain

  • Hopital 12 de Octubre

    Madrid, Spain

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.